EUVIMEDEUVIMED entdecken
Crossref

L26/P-837 Progestin- versus GnRH antagonist-based protocols in luteal phase ovarian stimulation: do clinical outcomes differ?

F. Göde, K. Boynukalın, Y.A. Tohma, M. Bahçeci, G. Bozdağ

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von F. Göde und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Are clinical outcomes different between GnRH antagonist and progestin-primed protocols used during luteal phase ovarian stimulation? Summary answer Overall clinical outcomes were comparable between the two protocols, although the progestin group yielded a slightly higher number of oocytes. What is known already Luteal phase stimulation (LPS) is increasingly used in fertility preservation, poor ovarian responders, and time-constrained ovarian stimulation cycles. To prevent premature LH surges during LPS, both progestins and GnRH antagonists are commonly employed. Although both approaches appear safe and effective, direct comparative data evaluating their clinical outcomes in LPS cycles remain limited. Study design, size, duration This retrospective study included 586 patients who underwent luteal phase ovarian stimulation. Of these, 242 received a GnRH antagonist protocol and 344 a progestin-primed protocol. Primary outcomes assessed included the number of retrieved oocytes, embryos obtained. Secondary outcomes were pregnancy and live birth rates. Protocol allocation was independent of patient characteristics and reflected routine clinical practice in our center. Clinical practice shifted from GnRH antagonist to progestin-primed protocols over time due to cost and feasibility. Participants/materials, setting, methods The study population consisted of infertile patients undergoing luteal phase stimulation cycles. Propensity score matching was applied to adjust for baseline demographic differences, resulting in 224 matched patients in each of the GnRH antagonist and progestin groups. Group comparisons were conducted using the Mann–Whitney U test, and logistic regression analysis was used to assess factors associated with pregnancy and live birth outcomes. Main results and the role of chance After propensity score matching, baseline characteristics were well balanced between the two groups, with standardized mean differences below 0.1 for all covariates, indicating adequate comparability. The progestin-primed group demonstrated significantly higher numbers of retrieved oocytes (7±7.35 vs 5.83±6.897, p = 0.026), MII oocytes (5.57±6.08 vs 4.22±5.26, p = 0.009), increased number of obtained embryos (4.34±4.95 vs 3.07±4.09, p = 0.002) and increased number of available blastocyst formation rates (45.2% vs 35.9%, p = 0.036) compared with the GnRH antagonist group. Pregnancy outcomes were evaluated in patients who underwent embryo transfer. Despite the higher oocyte yield observed in the progestin group, no statistically significant differences were observed between the two groups in live birth rates (43.1% vs 32.3%, p = 0.109) following the first frozen embryo transfer cycle. Similarly, fertilization, pregnancy, and clinical pregnancy rates did not differ significantly between the groups. Limitations, reasons for caution The retrospective design of the study limits causal interpretation. Although propensity score matching was used to minimize baseline differences, the influence of unmeasured clinical or laboratory confounding factors cannot be entirely excluded. Wider implications of the findings In conclusion, both protocols produced similar clinical outcomes in luteal phase stimulation. However, progestin-based protocols were associated with a modest increase in the number of retrieved oocytes. Trial registration number No

Zitieren

APA

Göde, F., Boynukalın, K., Tohma, Y., Bahçeci, M., & Bozdağ, G. (2026). L26/P-837 Progestin- versus GnRH antagonist-based protocols in luteal phase ovarian stimulation: do clinical outcomes differ?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1164

Vancouver

Göde F, Boynukalın K, Tohma Y, Bahçeci M, Bozdağ G. L26/P-837 Progestin- versus GnRH antagonist-based protocols in luteal phase ovarian stimulation: do clinical outcomes differ?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1164

BibTeX
@article{Gde2026,
  author = {Göde, F. and Boynukalın, K. and Tohma, Y.A. and Bahçeci, M. and Bozdağ, G.},
  title = {L26/P-837 Progestin- versus GnRH antagonist-based protocols in luteal phase ovarian stimulation: do clinical outcomes differ?},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1164}
}
Kostenlos starten →